75N93021F00001↗
Sri International received this contract from National Institutes of Health Niaid, National Institutes of Health: $6.66M obligated so far for health r&d services; health care services; applied research. It runs to 2027-04-30.
Key facts · data as of Oct 23, 2026
- Recipient
- Sri International
- Awarding agency
- National Institutes of Health (Department of Health and Human Services)
- Contracting office
- National Institutes of Health Niaid (75N930)
- Obligated to date
- $6.66M
- Potential value
- $9.75M
- Ends
- 2027-04-30
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 23, 2026.
Cite this page: SpendQuery, Award 75N93021F00001, data as of Oct 23, 2026, https://spendquery.com/award?id=CONT_AWD_75N93021F00001_7529_75N93020D00011_7529
Sri International: all federal awards · Department of Health and Human Services: spending · National Institutes of Health Niaid: what it buys · The follow-on: recompete brief
DECORPORATION MCM PHASE 1 CLINICAL SAFETY STUDY
Up for re-bid: ends 2027-04-30. Recompete brief → · 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases ↗
What it is
- Product or service
- Health R&D Services; Health Care Services; Applied Research (PSC AN12)
- Industry
- Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) (NAICS 541715)
- Contracting office
- National Institutes of Health Niaid (75N930)
- Competition
- Full and open competition
- Pricing
- Cost plus fixed fee
- How it was bought
- Single-award IDIQ · under 75N93020D00011
- Where the work is
- San Mateo, CA · district CA-15
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
5 subawards totaling $1.58M (23.7% of what was obligated), as Sri International reported them. Primes report subawards of $30,000 or more; smaller ones and unreported ones aren't here.
| Subcontractor | Amount | Subawards | Where | First | Last |
|---|---|---|---|---|---|
| Trialwise Inc | $1.09M | 2 | CA | 2023-10-19 | 2024-11-25 |
| CCS Associates, Inc. | $412.2K | 1 | CA | 2023-12-20 | 2023-12-20 |
| Jackson Laboratory | $38.3K | 1 | ME | 2025-06-19 | 2025-06-19 |
| Avantor Inc | $34.5K | 1 | VA | 2025-06-17 | 2025-06-17 |
The largest single subawards
| Date | To | Amount | For |
|---|---|---|---|
| 2023-10-19 | Trialwise Inc | $757.6K | SERVICES |
| 2023-12-20 | CCS Associates, Inc. | $412.2K | HOPO COHORT 7 - REGULATORY SUPPORT |
| 2024-11-25 | Trialwise Inc | $336.8K | HOPO CLINICAL TRIAL - CLOSEOUT / REPORTING |
| 2025-06-19 | Jackson Laboratory | $38.3K | LAB MICE |
| 2025-06-17 | Epl Pathology Archives, LLC | $34.5K | ARCHIVE SERVICES FOR SAMPLES/DATA |
Every action
7 actions since 2023-08-18. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-02-18 | P00010 | Administrative change | $0 | DECORPORATION MCM PHASE 1 CLINICAL SAFETY STUDY |
| 2025-05-13 | P00009 | Option exercised | $839.1K | DECORPORATION MCM PHASE 1 CLINICAL SAFETY STUDY |
| 2025-03-13 | P00008 | Option exercised | $1.30M | DECORPORATION MCM PHASE 1 CLINICAL SAFETY STUDY |
| 2024-10-31 | P00007 | Option exercised | $1.26M | DECORPORATION MCM PHASE 1 CLINICAL SAFETY STUDY |
| 2024-07-29 | P00006 | Option exercised | $1.26M | DECORPORATION MCM PHASE 1 CLINICAL SAFETY STUDY |
| 2023-12-05 | P00005 | Funding only | $1.64M | DECORPORATION MCM PHASE 1 CLINICAL SAFETY STUDY |
| 2023-08-18 | P00004 | Funding only | $363.2K | DECORPORATION MCM PHASE 1 CLINICAL SAFETY STUDY |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-23). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗